1 of 1
Story summary
- Eli Lilly & Company (LLY) is viewed as a strong investment due to its pipeline, including incretin therapies, with analysts' average brokerage recommendation of 1.63.
- The company plans a $6.5 billion biomanufacturing plant in Houston to boost capacity.
- Shares rose 5% after news of a potential White House drug-pricing agreement.
- Earnings rose 37.6% year-over-year with EPS of $6.31.
